Arcutis Biotherapeutics Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases. Its portfolio is comprised of topical treatments with potential to address immune-mediated dermatological diseases and conditions, or immuno-dermatology. Its strategy is to identify and develop treatments against validated biological targets in dermatology that deliver a differentiated clinical profile that addresses major shortcomings of existing therapies in targeted indications. Its products pipelines include ARQ-151, ARQ-154, ARQ-252 and ARQ-255.